Boehringer Ingelheim

Boehringer Ingelheim is a leading research-driven biopharmaceutical company, creating value through innovation in areas of high unmet medical need.

One of the world’s largest manufacturers of biopharmaceuticals, Boehringer Ingelheim is an industry pioneer and has produced more than 40 commercial biopharmaceuticals. Our contract manufacturing business, Boehringer Ingelheim BioXcellence™ reliably supplies innovative therapies that transform lives, today and for generations to come and creates solutions with its partners to improve patient health through its production network spanning the globe, from Biberach, Germany to Vienna, Austria, Shanghai, China and Boehringer Ingelheim Fremont Inc., in California, United States.

A mammalian cell culture center in the San Francisco Bay Area, Boehringer Ingelheim Fremont, Inc., has more than 600 scientists and specialists committed to research, development, and manufacturing to deliver high quality medicines for patients. Our modern facility offers high flexibility with stainless steel and single-use bioreactors for fed-batch and process intensification technology manufacturing. With the complete range of services, from cell line and strain development, including high expression systems, through process development and large-scale manufacturing, to Fill & Finish we help our customers to turn innovative biologic ideas into commercial reality.

6701 Kaiser Drive
Fremont, CA 94555 US
NEWS
The biopharma industry ended February and began March with plenty of clinical trial news. BioSpace shares the highlights.
Biopharma and life sciences organizations from across the globe provide updates on their businesses and pipelines.
On Sunday, Boehringer Ingelheim tweeted a message of support for Ukraine, and announced it was standing in solidarity with the embattled Eastern-European country.
FDA
Eli Lilly’s Jardiance scores expanded heart failure approval from the FDA and will now be available to all patients with heart failure to reduce the risk of death and hospitalization.
Novo Nordisk and Dicerna are no strangers. The companies have been collaborating on the development of RNAi therapies for liver disease for the past three years.
Three companies have posted major developments in the field of heart disease therapy.
It was another busy week for clinical trial news. Here’s a look.
The U.S. FDA greenlit a new indication for Gilead Sciences’ drug Biktarvy for pediatric patients with HIV who are virologically suppressed or new to antiretroviral therapy.
It was a busy week for clinical trial news. Here’s a look.
JOBS
IN THE PRESS